Trelegy Ellipta FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved September 18, 2017)
Brand name: Trelegy Ellipta
Generic name: fluticasone furoate, umeclidinium and vilanterol
Dosage form: Inhalation Powder
Treatment for: COPD, Asthma, Maintenance
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is an inhaled corticosteroid, long-acting muscarinic antagonist (LAMA), and long-acting beta2-adrenergic agonist (LABA) combination indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), and the maintenance treatment of asthma in patients aged 18 years and older.
Development timeline for Trelegy Ellipta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.